Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
10.1016/j.hrthm.2018.06.025 42
Phase 3 trials for Retatrutide are currently enrolling participants across North America, including sites in Canada
Its value is in identifying functional pathway abnormalities that may deserve further investigation or nutritional support
Long-Term Protocols: The most clinically relevant studies evaluated subcutaneous doses of 0.25 mg (250 mcg), 0.5 mg (500 mcg), and 1 mg (1,000 mcg) administered daily for 24 weeks
US$ 24.72
US$ 21.29
US$ 28.58
